Naloxone in chronic schizophrenic patients: Neuroendocrine and behavioral effects

Joel E. Kleinman; Daniel R. Weinberger; Alan Rogol; David J. Shiling; Wallace B. Mendelson; Glenn C. Davis; William E. Bunney; Richard Jed Wyatt

doi:10.1016/0165-1781(82)90047-6

Naloxone in chronic schizophrenic patients: Neuroendocrine and behavioral effects

Joel E. Kleinman, Daniel R. Weinberger, Alan Rogol, David J. Shiling, Wallace B. Mendelson, Glenn C. Davis, William E. Bunney, Richard Jed Wyatt

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

Naloxone produced improvement in abnormal thought content in medicated chronic schizophrenic patients, but not in drug-free patients. In contrast, drowsiness and increases in plasma prolactin concentrations were seen only in drug-free schizophrenic patients. Although growth hormone concentrations increased in drug-free and medicated schizophrenic patients, the time course was different in the two groups. Neuroleptics appear to alter naloxone's clinical and neuroendocrine effects in chronic schizophrenic patients.

Original language	English (US)
Pages (from-to)	1-7
Number of pages	7
Journal	Psychiatry research
Volume	7
Issue number	1
DOIs	https://doi.org/10.1016/0165-1781(82)90047-6
State	Published - Aug 1982
Externally published	Yes

Keywords

Naloxone
growth hormone
neuroleptics
prolactin
schizophrenia

ASJC Scopus subject areas

Psychiatry and Mental health
Biological Psychiatry

Access to Document

10.1016/0165-1781(82)90047-6

Cite this

@article{478347c915fd43c891686765111496e0,

title = "Naloxone in chronic schizophrenic patients: Neuroendocrine and behavioral effects",

abstract = "Naloxone produced improvement in abnormal thought content in medicated chronic schizophrenic patients, but not in drug-free patients. In contrast, drowsiness and increases in plasma prolactin concentrations were seen only in drug-free schizophrenic patients. Although growth hormone concentrations increased in drug-free and medicated schizophrenic patients, the time course was different in the two groups. Neuroleptics appear to alter naloxone's clinical and neuroendocrine effects in chronic schizophrenic patients.",

keywords = "Naloxone, growth hormone, neuroleptics, prolactin, schizophrenia",

author = "Kleinman, {Joel E.} and Weinberger, {Daniel R.} and Alan Rogol and Shiling, {David J.} and Mendelson, {Wallace B.} and Davis, {Glenn C.} and Bunney, {William E.} and Wyatt, {Richard Jed}",

year = "1982",

month = aug,

doi = "10.1016/0165-1781(82)90047-6",

language = "English (US)",

volume = "7",

pages = "1--7",

journal = "Psychiatry research",

issn = "0165-1781",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

TY - JOUR

T1 - Naloxone in chronic schizophrenic patients

T2 - Neuroendocrine and behavioral effects

AU - Kleinman, Joel E.

AU - Weinberger, Daniel R.

AU - Rogol, Alan

AU - Shiling, David J.

AU - Mendelson, Wallace B.

AU - Davis, Glenn C.

AU - Bunney, William E.

AU - Wyatt, Richard Jed

PY - 1982/8

Y1 - 1982/8

N2 - Naloxone produced improvement in abnormal thought content in medicated chronic schizophrenic patients, but not in drug-free patients. In contrast, drowsiness and increases in plasma prolactin concentrations were seen only in drug-free schizophrenic patients. Although growth hormone concentrations increased in drug-free and medicated schizophrenic patients, the time course was different in the two groups. Neuroleptics appear to alter naloxone's clinical and neuroendocrine effects in chronic schizophrenic patients.

AB - Naloxone produced improvement in abnormal thought content in medicated chronic schizophrenic patients, but not in drug-free patients. In contrast, drowsiness and increases in plasma prolactin concentrations were seen only in drug-free schizophrenic patients. Although growth hormone concentrations increased in drug-free and medicated schizophrenic patients, the time course was different in the two groups. Neuroleptics appear to alter naloxone's clinical and neuroendocrine effects in chronic schizophrenic patients.

KW - Naloxone

KW - growth hormone

KW - neuroleptics

KW - prolactin

KW - schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=0020367707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020367707&partnerID=8YFLogxK

U2 - 10.1016/0165-1781(82)90047-6

DO - 10.1016/0165-1781(82)90047-6

M3 - Article

C2 - 6127744

AN - SCOPUS:0020367707

SN - 0165-1781

VL - 7

SP - 1

EP - 7

JO - Psychiatry research

JF - Psychiatry research

IS - 1

ER -

Naloxone in chronic schizophrenic patients: Neuroendocrine and behavioral effects

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this